What is Zacks Research’s Estimate for CRL Q4 Earnings?

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at Zacks Research increased their Q4 2025 EPS estimates for Charles River Laboratories International in a research note issued on Monday, February 2nd. Zacks Research analyst Team now anticipates that the medical research company will earn $2.32 per share for the quarter, up from their previous forecast of $2.31. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q1 2026 earnings at $2.39 EPS, Q4 2026 earnings at $2.92 EPS, Q1 2027 earnings at $2.43 EPS and Q4 2027 earnings at $3.25 EPS.

A number of other brokerages also recently issued reports on CRL. Citigroup upped their price objective on Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Barclays boosted their price target on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Bank of America upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective for the company in a report on Monday, December 15th. Mizuho set a $215.00 target price on shares of Charles River Laboratories International in a research note on Friday, January 9th. Finally, Wall Street Zen downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, January 23rd. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $209.46.

Charles River Laboratories International Stock Performance

CRL stock opened at $201.28 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. The firm has a market cap of $9.91 billion, a PE ratio of -129.03, a P/E/G ratio of 6.04 and a beta of 1.63. The business has a 50 day moving average of $204.01 and a 200-day moving average of $179.46. Charles River Laboratories International has a 12-month low of $91.86 and a 12-month high of $228.88.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $990.43 million. During the same period in the prior year, the firm posted $2.59 EPS. The firm’s quarterly revenue was down .5% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CRL. Madison Asset Management LLC lifted its position in shares of Charles River Laboratories International by 26.3% during the fourth quarter. Madison Asset Management LLC now owns 15,622 shares of the medical research company’s stock worth $3,116,000 after acquiring an additional 3,256 shares in the last quarter. Swiss Life Asset Management Ltd raised its stake in shares of Charles River Laboratories International by 6.0% during the 4th quarter. Swiss Life Asset Management Ltd now owns 2,342 shares of the medical research company’s stock valued at $467,000 after purchasing an additional 132 shares during the period. NewEdge Wealth LLC bought a new stake in shares of Charles River Laboratories International during the 4th quarter valued at $515,000. Gateway Investment Advisers LLC purchased a new stake in Charles River Laboratories International during the 4th quarter worth about $666,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Charles River Laboratories International by 4.3% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 58,397 shares of the medical research company’s stock worth $11,821,000 after purchasing an additional 2,391 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.